According to Zacks, “IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated. “
Separately, Northland Securities started coverage on Isoray in a research note on Tuesday, September 14th. They issued an outperform rating and a $1.25 price objective for the company.
Isoray (NYSEAMERICAN:ISR) last announced its quarterly earnings data on Wednesday, November 10th. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The business had revenue of $2.56 million during the quarter, compared to analysts’ expectations of $2.58 million. Isoray had a negative return on equity of 9.19% and a negative net margin of 48.05%. On average, equities analysts forecast that Isoray will post -0.04 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of ISR. Geode Capital Management LLC raised its stake in shares of Isoray by 13.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,119,070 shares of the healthcare company’s stock valued at $892,000 after acquiring an additional 134,843 shares in the last quarter. Bard Associates Inc. raised its stake in shares of Isoray by 40.3% in the 2nd quarter. Bard Associates Inc. now owns 537,400 shares of the healthcare company’s stock valued at $429,000 after acquiring an additional 154,400 shares in the last quarter. State Street Corp raised its stake in shares of Isoray by 4,807.3% in the 2nd quarter. State Street Corp now owns 519,042 shares of the healthcare company’s stock valued at $414,000 after acquiring an additional 508,465 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Isoray by 300.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 99,229 shares of the healthcare company’s stock valued at $80,000 after acquiring an additional 74,426 shares in the last quarter. Finally, Morgan Stanley raised its stake in shares of Isoray by 3,364.7% in the 2nd quarter. Morgan Stanley now owns 76,224 shares of the healthcare company’s stock valued at $61,000 after acquiring an additional 74,024 shares in the last quarter. 11.16% of the stock is owned by institutional investors.
Isoray Company Profile
IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
Featured Story: What is the cash asset ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.